Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"CYTX's upcoming ATHENA clinical data will be a major catalyst for the company, giving confidence not only to investors but also to the physician community." (11/14/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >
"INO has extraordinary potential; I really want to see CEO Joseph Kim and Dave Weiner push this technology into the future." (10/24/13) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Patrick Cox More >
"CPRX is an emerging biotechnology company in the white hot space of orphan drug medicines." (11/7/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Scott Henry More >
"BDSI's buprenorphine product for chronic pain could be a $500M+/year revenue-generating drug if approved." (11/7/13) BioDelivery Sciences International Inc. - The Life Sciences Report Interview with Scott Henry More >
Companies Commented On
- Alphatec Holdings, Inc.
- ArthroCare Corp.
- BioMimetic Therapeutics, Inc.
- China Kanghui Holdings
- Cyberonics Inc.
- Derma Sciences, Inc.
- Dexcom Inc.
- Echo Therapeutics Inc.
- EnteroMedics Inc.
- Exactech Inc.
- Globus Medical Inc.
- Insulet Corp.
- Integra LifeSciences Holdings
- Intuitive Surgical Inc.
- Johnson & Johnson
- MAKO Surgical Corp.
- Medtronic Inc.
- NuVasive Inc.
- NxStage Medical Inc.
- Obagi Medical Products, Inc.
- Orthofix International N.V.
- Palomar Medical Technologies
- RTI Biologics Inc.
- Solta Medical Inc.
- Stryker Corporation
- TranS1 Inc.
- Valeant Pharmaceuticals International Inc.
- Zimmer Holdings, Inc.
William Plovanic joined Canaccord in 2007 as a managing director, medical technology equity research analyst. He has been a publishing sell-side analyst with coverage of medical devices for over 15 years. Plovanic's areas of coverage include orthopedics, diabetes, obesity, neuro-technologies, dialysis, aesthetics and general surgery. In 2009 he was ranked as the #2 Earnings Estimator for health care equipment & supplies by Starmine. Furthermore, in 2003 and 2004, he was selected as a Wall Street Journal "All Star" analyst in the medical device sector and in 2002 was named the #1 ranked analyst by Starmine for stock picking and performance in the medical technology sector. He is a frequent presenter at medical and industry meetings. Prior to Canaccord, Mr. Plovanic was a managing director and senior research analyst at First Albany (now Gleacher & Company). Previously, he worked at PMG Capital covering medical devices and products. Plovanic also worked as director of research for the Capital Markets Division of LaSalle St. Securities Inc., where he focused on the small-cap healthcare, technology and biotechnology industries. He graduated from Bradley University with a Bachelor of Science in finance and is a Chartered Financial Analyst.
What Will Boost Medtech Stocks? Look for a Better Mousetrap, Says William Plovanic (2/21/13) Growth in the medical technology industry may have slowed, and governmental hurdles may make the forecast gloomy, but value plays await the investor who understands how innovation can drive company stock prices upward. In this interview with The Life Sciences Report, William Plovanic, analyst and managing director with Canaccord Genuity, talks about his top names in medtech and why he believes investors need to take advantage of the slowdown now. He also ruminates on the potential effects of Obamacare's impending implementation.
Special Report from the ADA: William Plovanic Identifies Companies with Promising Diabetes Solutions, Prospects (6/21/12) Every year, top researchers and physicians meet at the American Diabetes Association Scientific Sessions. This year, Canaccord Genuity Analyst and Managing Director William Plovanic reported back on promising developments and what they could mean for the companies behind them. In this interview with The Life Sciences Report, he explains why he is so positive on the space in general and about certain companies in particular.
Choose Medical Technology Stocks Carefully: William Plovanic (3/15/12) The dart board will not help in picking medical technology stocks. Analyst and Managing Director William Plovanic of Canaccord Genuity focuses on the musculoskeletal/orthopedic sector, which is sensitive to factors beyond just the unmet needs of patients. Economic and regulatory dynamics make it difficult to predict growth in medtech, but in this exclusive interview with The Life Sciences Report, veteran analyst Plovanic delivers both ideas and names that could generate excellent returns for investors.
"If approved by the FDA, MDT's MiniMed 530G system will be the only integrated insulin pump and continuous glucose monitor in the U.S. that automatically suspends insulin delivery if the sensor glucose value is equal to or below the low threshold value." (6/21/12) Medtronic Inc. - The Life Sciences Report Interview with William Plovanic More >
"CPRX has a few programs in indications that are less crowded and do not have many successful treatment options." (11/26/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Michael Hay More >
"ATHX's MultiStem phase 2 data are going to be very important for investors if the trial is positive for patients." (11/26/13) Athersys Inc. - The Life Sciences Report Interview with Michael Hay More >
"We expect FDA approval in the near term—likely by the end of the year—for OCLS' Microcyn Hydrogel device." (11/26/13) Oculus Innovative Sciences Inc. - The Life Sciences Report Interview with Jocelyn August More >